Nonetheless, PCR-based assessment of mtDNA damage remains a promising biomarker for LRRK2 pharmacodynamics and potentially the identification and stratification of PD patients who have elevated LRRK2 activity but without a LRRK2 mutation. The gene discussed is LRRK2; the disease is Parkinson disease.